KoalaT.ai

As a Freelance Project Manager, I specialize in regulatory compliance and quality management services for the medical device industry. My goal is to ensure that medical device companies achieve full compliance with FDA, ISO, and EU MDR regulations, while optimizing quality systems and operational efficiency.

Services Provided:

Regulatory Compliance Audits: Conduct comprehensive audits to evaluate and ensure compliance with FDA, ISO 13485:2016, and other relevant regulations.

Supplier Quality Management: Implement strategies to improve supplier performance, reduce costs, and enhance quality across the supply chain.

AI-Driven Compliance Solutions: Leverage AI technology to streamline compliance processes and provide data-driven insights for decision-making.

Process Optimization: Manage projects that optimize processes to improve efficiency and compliance readiness.

Flexible Engagement Options:
-Hourly Ad Hoc
-Short-Term Projects
-Long-Term Contractual Agreements (Remote or Onsite)

Industries Served:
-Medical Devices
-Pharmaceuticals
-In-Vitro Diagnostics

Specialized Audit Services:
FDA Mock Inspections
CAPA Management
ISO 13485:2016 Compliance
Supplier Audits
Quality System Audits (21 CFR Parts 820)
Multi-Country Registration & Approvals (US 510K, EU CE Mark)

Key Achievements:
Successfully reduced audit findings by up to 95% for multiple clients.
Developed and implemented AI-driven tools to optimize compliance processes, resulting in significant efficiency gains.

Contact Information:
If your organization needs expert guidance to navigate regulatory challenges and ensure quality compliance, feel free to connect with me here on LinkedIn or via email Neel@KoalaT.ai

Fractional Project Manager

Medtronic

• Led Audit Readiness program for Global Field Corrective Action (recalls) and Product Hold Order across four portfolios, enhancing audit preparation and execution.
• Collaborated with cross-functional teams to implement effective audit strategies, significantly reducing findings and ensuring compliance.

Enterprise Audit Readiness Program Manager

Endologix LLC

• Managed Supplier Change program to maintain supply chain continuity and oversee product lifecycle management
• Ensured design review, risk assessment, and control establishment in cross-functional teams
• Drove the completion of over 70+ supplier change evaluations and achieved EU MDR compliance
• Acted as front room SME during FDA, NSAI, ANVISA, and GMED audits and leveraged cross-functional SMEs in the backroom

Sr. Supplier Quality Engineer 

• Led cross-functional teams to complete Quality Impact Assessment, Component Qualification, and Supplier development
• Achieved design improvements, supplier changes, quality objectives, and supplier selection
• Led non-conformance investigations, and supported continuous improvement initiatives

Sr. Supplier Quality Engineer (Neurovascular)

Phillips-Medisize

• Implemented strategies for driving product quality and continuous improvement for Class I-III Medical Devices
• Developed CAPA documentation in partnership with suppliers, customers, and PMCM for effective root cause analysis and corrective action

Lead Supplier Quality Engineer

Alcon

•	Primary supplier quality contact for surgical consoles, PCB, and consumable product lines
•	Responsible project owner of supplier data analysis utilized in implementing updated Approved Supplier List (ASL) and retirement of suppliers in Supplier Review
•	Responsible for supplier’s qualification, assessment, review, and approval. Supplier surveys, Supplier Quality Risk Assessments, supplier certifications, first time buy approvals and Quality Agreements 
•	Provided Component Risk Assessments and verification by analysis for ultimate drawing updates in Engineering Change Notifications (ECN)
•	Provided assessment of dock to stock inspection data analysis of components 
•	Created and approved closure of quality notifications in SAP, gathered data regarding the supplier and the current inventory needing containment activities to ensure the production schedule could be met
•	Communicated Receiving Inspection & WIP defects to suppliers through the use of Supplier Action Request (SAR)/CAPA system
•	Completed training for basic auditor and (desktop) virtual auditing on Quality Management Systems to ensure conformance (ISO 9001 and 13485, CFR 21)
•	Responsible for project analyzing documentation, data, inspection, and drawings updates for safety critical components and compliance 
•	Resolved quality issues of capability, tolerance, and material related issues
•	Collaborated with suppliers, vendors, and teams of engineers to troubleshoot reoccurring nonconformances and safety critical issues 
•	Capable of managing large data and sharing statistical interpretation 
•	Experience with medical device production, process improvement and project management
•	Experience communicating with outside vendors and suppliers on cost contracts, technical drawings, production processes, and project needs
•	High understanding of team’s manufacturing and documentation process

Supplier Quality Engineer 

Chegg Inc.

• Assisted students with test taking tips and strategies. 
• Multitasked and prioritized independent work. 
• Tracked and analyzed student progress. 
• Communicated effectively with parents and staff.
• Helped students build knowledge on difficult topics such as preparing for SAT. SAT subject tests, and ACT as well as physics, chemistry, biology, biochemistry, and engineering.

Chegg Tutor

Torticollar (Sr. Design Project)

Slashed production costs from $2000 to $100 per unit.
Negotiated contracts with outside mass manufacturing suppliers.
Managed production, process improvement, prototyping, benchmarking, bench testing, 3-D printing, business team operation, as well as generated investor reports and presentations.
Investigated patent approval with medical patent lawyer consultation.

Quality Engineer / Research & Development		

University of California, Riverside Pediatric Rehabilitation Technology Lab

Using logistical models, conducted data analysis, obtaining measurements, performing study design and research methodology, as well as research-related activities, and initiating programming activities using MATLAB coding for examination of novel neuro-rehabilitation environments that aim to improve physical function and promote the development of children with motor disorders.

Research Assistant

Riverside Healthcare

Managed front desk, assisting patients with checking in, operating kiosks, and providing directions to various places within the facility. Also assisted with discharge and the transport of patients through the hospital and to their vehicles.

Volunteer

Program Manager | Supplier Management, Medical Device Auditor, AI

I help medical device startups and SMBs in the Midwest conquer FDA, ISO 13485, and EU MDR audits with confidence. 

I'm a certified Quality professional with 3+ years of experience building and optimizing compliant, efficient systems, specializing in:

Audit Readiness: Developing and implementing robust programs that streamline preparation and minimize findings.

Supplier Quality Management: Ensuring your suppliers meet the highest standards, reducing risk and improving your supply chain.

AI-Powered Solutions: Leveraging cutting-edge technology to enhance efficiency, provide data-driven insights, and create a proactive approach to compliance.

I have a proven track record of successfully leading projects that transform quality systems and deliver tangible results. 

For example, at a global medical device company, I spearheaded an enterprise-wide audit readiness program that reduced audit findings by over 95% while simultaneously supporting a remote Warning Letter re-inspection, ensuring a smooth and efficient process that led to the Warning Letter being lifted.

Building strong supplier relationships and navigating the complex regulatory landscape are also key areas where I excel. My data-driven approach, combined with a deep understanding of AI applications, allows me to solve complex problems and deliver solutions that directly impact your bottom line.

I hold multiple certifications in quality auditing (Certified Medical Device Auditor, Supplier Quality Professional, and Quality Auditor) and have a strong background in Biomedical Engineering (B.S.) and Technology & Innovation Management (M.S.). I've completed specialized coursework in AI in Healthcare & Biotech and Pharma from MIT Sloan School of Business, further enhancing my expertise in leveraging AI to solve real-world challenges in the medical device industry.

As a lifelong learner, I am dedicated to staying current with the latest trends, tools, and technologies, and sharing that knowledge with others. In my spare time, I enjoy testing AI devices and models, riding One-Wheel, home improvement, and producing electronic music.

If your medical device company needs a seasoned project manager who can step in and drive your critical projects to success, let’s connect.

I’m currently offering a complimentary discovery call to discuss how we can work together to streamline your projects, ensure compliance, and bring your life-saving technologies to market more efficiently.

24 days under QMSR.

The first post-QMSR FDA inspections have already happened.

Darren Reeves walked a client through one last week and shared the findings publicly. Over 90 quality professionals engaged — including a current FDA investigator.

His #1 takeaway:
"Risk, Risk, Risk. Organize your devices by FDA product code and highest risk. That is where they will start."

Not CAPA. Not complaints. Not document control.
Risk.

A second consultant reported a parallel experience: the investigator opened with two requests:
"Let me see your quality plan for QMSR."
"Let me see your procedure for risk analysis."

From there, the investigator walked through every QMSR gap to test it.
So here's what we know 24 days in:

Investigators are leading with risk documentation

At least one investigator had challenges interpreting ISO 14971
CAPA, purchasing, management review all came AFTER risk

Meanwhile, I ran 7 recent FDA warning letters through our analysis engine:
23 deficiencies. 10 critical. 13 major.

The #1 clause? 8.5.2 — Corrective Action. In 5 of 7 letters (71%).

Average risk score: 77.1 out of 100.

The pattern is clear:

Inspectors are starting with risk (new).
But CAPA remains the most common citation (consistent).
The companies getting cited can't trace complaints back to their risk file.

Three things to do before your next inspection:

1. Organize your devices by product code and risk class. Don't make the investigator build that hierarchy.
2. Pull your FMEA. Does it reflect current field data — or original design assumptions from 3 years ago?
3. Can you trace a complaint through investigation to a risk file update? If not, that's the gap they'll find.

The enforcement pattern isn't theoretical anymore.
It's here.

#QMSR #FDA #MedicalDevice #QualityManagement #ISO13485 #CAPA #RiskManagement

undefined undefined

Medical Device Quality & Regulatory Consultant | FDA, ISO 13485, 510(k) & CAPA Expert | Helping Manufacturers Navigate Compliance & Operational Success | Published Author

Founder & CEO @ QMS.Coach | AI-Accelerated MedTech Compliance | Building the “Virtual Backroom” | PMP, CMDA, CQA, ISO 13485 Lead Auditor

I spent an hour today in a room with AI power users from Google, Johnson & Johnson, Big 4 consulting, and pharma strategy.

One person demoed a regulatory horizon scanner built entirely with Gemini — industry, jurisdiction, framework, and it maps the full compliance landscape in minutes.

Another described how Claude has replaced four standalone apps in their personal life. Financial tracking. To-do lists. Fitness. Gone.

I shared a story about Meta acquiring the app that held 3 years of my screen data — and the system I built after they killed it.

But the concept that got the strongest reaction wasn't technical.

It was a governance pattern coined a Constitution by one of the founding members— a set of rules your AI follows across every session. Voice. Boundaries. Decision-making frameworks.

One person stopped the conversation and said: "I'm taking that."
And the longest discussion — roughly 15 minutes — wasn't about any tool.

It was about security.

The gap between what consumer AI can do and what you're actually allowed to feed it with client data. Everyone in the room felt it. Nobody had solved it.

That tension — between capability and confidentiality — is the real bottleneck for knowledge workers adopting AI in regulated industries.

Not the models. Not the prompts. The trust architecture.

Full breakdown — tools shared, patterns that landed, and the security question nobody has answered yet — in this Sunday's QMS.Coach LLC. newsletter.

QMSR took effect 5 weeks ago.
The gap analyses should be done. The crosswalk spreadsheets should be filed.
Here's what I'm actually seeing in the field.

OBSERVATION 1: CAPA is the enforcement magnet. Again.
I've been analyzing FDA warning letters across medical device manufacturers.
The pattern is unmistakable:
→ Corrective and preventive action deficiencies appear in 5 of the last 7 warning letters I reviewed
→ Average risk severity across those findings: 77 out of 100
→ 10 critical findings. 13 major. Zero minor.

Under the old 820, CAPA (820.100) was the #1 483 observation for over a decade.

Under QMSR, it maps to ISO 13485 Clauses 8.5.2 and 8.5.3
The enforcement priority didn't change. The clause number did.
If you read my post two weeks ago about CAPA metrics, this is the data underneath it. Effectiveness reviews, recurrence tracking, investigation depth — these aren't theoretical gaps. They're where warning letters land.

OBSERVATION 2: Your ISO 13485 certificate won't save you.
I keep hearing this: "We're already 13485 certified. QMSR is paperwork for us."
This is dangerous thinking.
Your notified body interpreted ISO 13485 one way.
FDA interprets it another way.
Same clauses. Different enforcement standards.
ISO 13485 Clause 7.1 requires planning of product realization "appropriate to the operations of the organization."
Your NB accepted your definition of "appropriate."
FDA might not.
The companies I'm watching closely are the ones re-reading 13485 through FDA's lens — not their notified body's lens.
Those are very different lenses.

OBSERVATION 3: Management review is the sleeper gap.
Under 820, management review lived in 820.20(a). It was broad. Many companies ran it as a yearly slide deck.
Under QMSR, management review maps to Clause 5.6 — and the requirements are significantly more specific:
→ Defined review inputs (5.6.2): feedback, complaint handling, process performance, CAPA status, changes affecting the QMS
→ Defined review outputs (5.6.3): improvement actions, resource needs, documented QMS changes
If your management review has no traceable connection to your CAPA trends, complaint data, and process metrics — you have a gap.
And it's the kind of gap that looks systemic to an investigator.

OBSERVATION 4: The gap analysis trap.
Companies that weren't 13485 certified before Feb 2 are buried in gap analysis spreadsheets right now.
I've seen organizations with 200+ identified gaps and no triage methodology.
Not all gaps are equal.
A gap in Clause 4.1.5 (outsourced process control) affecting your critical sterilization supplier is fundamentally different from a gap in Clause 4.2.4 (record control) that requires updating a form header.
If you don't risk-rank your gaps, you'll close 50 documentation gaps and miss the 3 systemic ones an investigator would actually cite.

(CONTINUED IN THE COMMENTS...)

The FDA just told you to stop scripting your test cases.

Most QMS teams heard "CSA replaces CSV" and thought it meant less work.
It means different work.

Computer System Assurance under GAMP 5 Second Edition asks one question traditional validation never did:

Can you show me your critical thinking?

Not your test scripts. Not your traceability matrix. Your actual reasoning for why these tests matter and those don't.

That's harder than following a protocol. A protocol tells you what to do. CSA asks you to explain why you're doing it.

Three things that change under CSA:
→ Unscripted testing isn't just allowed — it's encouraged
→ Risk determines the depth of your records, not a template
→ The record of your thinking IS the evidence

The teams that struggle with this aren't lazy. They've been trained for 20 years to follow the script. Now the script is gone and the question is whether they can defend their own judgment.

That's the real transition. Not a new regulation. A new expectation of professional competence.

Saturday thought: What happens to validation when the answer to "why did you test this?" can't be "because the protocol said so"?

I inherited audit readiness for a department
with roughly 20 open internal audit findings.

All 4 Medtronic portfolios. Enterprise scope.
Cardiovascular, Diabetes, Medical Surgical, Neuroscience.

The next audit cycle?

1 finding. A minor.

That's a ~95% reduction. Here's what changed.

I stopped treating findings as individual problems.

Most audit remediation looks like whack-a-mole.
A finding comes in. Someone writes a CAPA.
The CAPA closes. A similar finding opens 6 months later.

Sound familiar?

The shift was building a system — not chasing symptoms.

→ Classified findings to see patterns, not just individual nonconformances
→ Mapped the processes that kept generating repeat findings
→ Tracked leading indicators so problems surfaced before the auditor did
→ Turned management review from theater into something that actually drove action

That last one matters most.

If your management review discusses audit findings
but nothing changes quarter to quarter —
you don't have a finding problem. You have a governance problem.

Under QMSR, this isn't optional anymore.

ISO 13485 Clause 8.5.2 (Corrective Action) and 8.2.2 (Internal Audit)
are now FDA requirements — not suggestions you can interpret loosely.

The companies that built the system before the deadline
aren't scrambling right now.

The ones that didn't? They're about to find out
what 20 open findings feels like.

I built a resource library with the templates
I wish I'd had when I started that program:

CAPA effectiveness checks. Audit day scripts.
QMSR clause mapping tables.

→ https://lnkd.in/gXdSNbbW

#QMSR #AuditReadiness #ISO13485 #CAPA #QualityManagement #MedicalDevices #FDA

You can't use ChatGPT for audit prep.

Not because the AI is bad. Because the audit trail doesn't exist.

When an FDA investigator asks how you arrived at a risk decision — and they will — "GPT told me" isn't an answer. There's no record of what you asked. No record of what it said. No way to verify the response hasn't changed. No attribution. No timestamps. No citations you can trace.

That's not a technology problem. That's a compliance problem.

This is what I kept running into when I was building VirtualBackRoom.ai. The AI was helpful. But in a regulated environment, helpful isn't enough. It has to be provable.

So here's what I built differently:

Every AI interaction is logged with SHA-256 hashes.
The prompt gets a hash. The response gets a hash. The full record gets a hash chained to the previous one. If anyone changes anything after the fact, the chain breaks. That's not a feature I invented — it's how 21 CFR Part 11 says electronic records should work. I just applied it to AI.

It doesn't rely on a single model.

A standalone GPT gives you one opinion from one system. VirtualBackRoom runs a council — multiple AI models reviewing the same question independently, each with different strengths. One is optimized for ISO standards and long regulatory documents. Another specializes in risk assessment and nuance. Another pulls live FDA enforcement data in real time.

When they agree, you have confidence. When they disagree, you know exactly where to dig deeper.

It follows ALCOA.

If you work in quality, you know ALCOA: Attributable, Legible, Contemporaneous, Original, Accurate. Every AI response in VirtualBackRoom is tied to a user, timestamped, preserved in its original form, and locked. You can't edit it after the fact. The record is the record.

It never goes down.

If one AI provider has an outage, the system routes to the next one automatically. If every external provider fails, there's a local fallback. In three years of building this, I've never had a situation where a user got no response. That matters when you're prepping for an audit with a deadline.

It's invite-only.

No public sign-ups. No free tier with unclear data handling. Every user is on a whitelist. That's a deliberate choice — in regulated environments, you need to know exactly who has access and when they used it.
—
I built this because I kept watching quality teams do one of two things:

Avoid AI entirely because they couldn't prove how it was used

Use ChatGPT privately and hope nobody asked

Neither is sustainable. QMSR is live. Audits are coming. And the teams that figure out how to use AI with a compliance trail — not instead of one — are going to move faster than everyone else.

VirtualBackRoom isn't a chatbot. 

It's a backroom — the place where your team talks through the hard decisions before the auditor walks in. Except now the backroom has 11 specialists who never sleep, never forget a citation, and leave a paper trail for everything.

virtualbackroom.ai

most AI compliance tools ask you to trust them.

i built one that assumes you shouldn't.

here's the security architecture behind virtualbackroom.ai — and why "trust me" is the wrong answer for regulated industries:

1. no training on your data.
every document you upload goes through analysis and comes back as structured output. nothing is stored for model training. nothing is retained after your session.

2. model routing, not model lock-in.
the system routes different tasks to different models based on the job — gap analysis goes to one, risk scoring goes to another, clause mapping goes to a third. no single model sees your full picture.

3. the audit trail isn't optional.
every AI-generated finding includes the source clause, the confidence level, and the reasoning chain. if the system can't show its work, the finding doesn't ship.

4. human review is architecturally required.
the system generates the analysis. a human reviews, accepts, or rejects each finding before it becomes part of any report. there is no "auto-approve" button. there never will be.

5. the validation layer.
before any output reaches the user, a separate validation process checks for hallucinated clause references, mismatched risk scores, and internal contradictions. 

the validator and the generator don't share context.
when someone asks me "but is AI ready for regulated work?"

my answer: the AI was ready a year ago. the question is whether the architecture around it respects the environment it's operating in.

building tools for medtech means building for auditors, not just users.

virtualbackroom.ai — FDA Warning Letter analysis powered by AI architecture built for regulated environments.

The AI systems of today are nowhere near reliable enough... anyone who's worked with AI models understands that there's a basic unpredictability to them that in a purely technical way we have not solved." [02:38]

​In a defining moment for AI governance, Anthropic CEO Dario Amodei recently sat down with CBS to explain why the company is drawing a hard line against deploying unrestricted AI for fully autonomous weapons and domestic mass surveillance.

​Beyond the politics, his core argument is fundamentally about Systems Engineering and Risk.

​Whether the context is national defense or Medical Device Quality Systems (QMS), the technical reality of Generative AI remains the same: you cannot blindly hand over the keys to a probabilistic "black box" for high-stakes, life-or-death decisions.

​At [18:37], Dario states: "The essence of our values is that we have to find a way to win in a way that preserves those values."

​This perfectly mirrors the tension we are seeing in the MedTech regulatory space. We cannot sacrifice safety and validation just to move faster. This is exactly why the industry must move toward Neuro-Symbolic AI architectures—where the creative, probabilistic LLM is strictly bounded by a deterministic Logic Layer (like ISO 13485).

​We need AI to act as a "Cognitive Orthotic" that amplifies human judgment, not a replacement that completely removes the Human-in-the-Loop. Without strict validation and oversight, we risk a complete systemic collapse of trust.

​Speaking of Collapse... 💔

​When I am not architecting AI compliance frameworks, I am usually balancing the left and right sides of my brain in the studio. 

I just dropped my newest electronic track: a remix of Zeds Dead's classic, "Collapse."

​If you need a high-energy, deep-focus soundtrack for your next knowledge-work sprint, throw the headphones on and give it a spin.

​📺 Watch the full Anthropic interview context here: https://lnkd.in/gFEtjjRH

🎧 Listen to Zeds Dead - Collapse (feat. Memorecks) [Neel Down Remix] here: https://lnkd.in/gAsfkGHU

​#ArtificialIntelligence #AIGovernance #Anthropic #MedTech #QualityAssurance #NeuroSymbolicAI #ZedsDead #MusicProduction #DualLife #open

A post by John Pryor caught my attention today.

He wrote about trade secrets hiding in plain sight
inside UK SMEs. The real IP isn't registered.
It's in processes nobody documented or protected.

He's right. But I want to apply his argument
to medical devices — where the blind spot is worse.

I studied this in grad school.

My engineering law coursework at Northcentral University
opened with all four types of IP:
Patents. Trademarks. Copyrights. Trade secrets.

My first assignment was conducting an IP inventory
for the Fortune 500 med-device company I worked at.

Not hypothetical. Real employer. Real IP.

I analyzed trade secret litigation where
manufacturing process settings — not products,
not formulas — process settings —
were disputed as protectable IP.

That changed how I think about trade secrets.

Under the Uniform Trade Secrets Act (UTSA),
a trade secret has two requirements:

1. It derives economic value
  from not being generally known.
2. The holder takes reasonable measures
  to keep it secret.

No registration. No filing. No expiration.

Now think about your quality system.

Your SOPs describe HOW you make
a safe, effective medical device.
Your CAPA procedures. Your validation protocols.
Your work instructions and engineering changes.

Does that derive economic value
from not being generally known?

Obviously. Your competitors would pay for it.
That's why they hire your people.

Do you take reasonable measures to protect it?

Most med-device companies treat QMS documentation
as compliance paperwork. Not protectable IP.

Access controls are loose.
Consultants reuse process knowledge elsewhere.
Employees leave with tribal knowledge.

No alarms. No headlines.
Just gradual erosion of your most defensible IP.

Here's where it gets interesting.

Under QMSR — effective February 2, 2026 —
ISO 13485 Clause 4.2.4 (Document Control)
and 4.2.5 (Control of Records) are now
FDA requirements.

What those clauses mandate:
→ Controlled access
→ Version management
→ Distribution tracking
→ Prevention of unintended use

What trade secret law requires
for "reasonable measures":
→ Controlled access
→ Need-to-know restrictions
→ Documentation of who has what
→ Evidence you enforced it

It's the same list.

QMSR compliance and trade secret protection
just became the same conversation.

Companies with proper document control
aren't just compliant — they're protecting
their most valuable IP without realizing it.

Two frameworks. Same controls. One system.

Most quality professionals see themselves
as compliance people. Not IP people.

But your quality system is often
the most valuable unregistered IP
in the entire company.

Templates for this intersection:
→ https://lnkd.in/gXdSNbbW

John Pryor — appreciate the post.
The regulated industry version of your argument
needs to be heard.

#QMSR #IntellectualProperty #TradeSecrets
#ISO13485 #MedicalDevices #FDA #DocumentControl

30 days ago i picked up publishing linkedin posts about QMSR once again.

i had 1,456 followers. zero consulting clients. a product nobody had heard of. and a notion, replit, and spreadsheet full of ideas i wasn't sure anyone cared about.

here's what february actually taught me about building in public in medtech:
the numbers:

40,155 impressions. 207 new followers. 69 new connections. one post that hit 850+ impressions and got shared by people i'd never met.

what worked:

— writing about real problems, not thought leadership theater
— the CAPA metrics post (day 14) broke through because it gave people something they could actually use on monday morning
— commenting on other people's content drove more connections than my own posts did
— the DMs that worked were the ones where i asked questions, not pitched services

what didn't:

— product-focused posts underperformed by 40% vs. problem-focused posts
— posting on weekends was a waste of time for this audience
— long posts without a clear "so what" got scrolled past
— trying to be clever instead of useful

what surprised me:

— the quality community on linkedin is smaller and more connected than i expected. everyone seems to know everyone.
— people respond to specificity. "here's what clause 8.5.2 means for your CAPA process" outperforms "QMSR is changing everything" by 3x.
— nobody cares about your product until they trust your perspective. content is the trust layer.

what's next:

march is about depth. fewer posts, more conversations. a newsletter launch. and the hardest part — turning followers into people who actually want to work together.

if you've been following along, thank you. genuinely. this stuff only works because people engage with it.

what's one thing you've learned building in public that you wish someone had told you earlier?

it's sunday afternoon and i'm writing prep notes for three major meetings next week while my coffee gets cold.

nobody tells you the real schedule of building something from scratch:

monday: client meeting prep + channel partner demo call.

tuesday: discovery call with a company 100x your size.

wednesday: virtual coffee with someone who's building something that makes yours better.

thursday: content writing.

friday: the admin work you avoided all week.

saturday: everything you told yourself you'd finish during the week.

sunday: the part where you tell yourself "next week will be different."

there's no team meeting. no standup. no one asks how the sprint went. you are the sprint.

the hardest part isn't the work. the hardest part is that nobody's watching to make sure you do it.

the second hardest part is knowing that if you don't, nothing happens. no email. no ping. just... nothing.

and somehow that silence is the most motivating thing i've ever experienced.

anyone else building on a sunday?

Applied a risk-based approach to determining my 90s celebrity doppelganger.

Severity: High
Occurrence: Undeniable  
Detection: Immediate

Conclusion: No corrective action needed. ✅

Have a great week, quality people.

#qmsr #riskmanagement #iso14971 #shahrukhkhan #90s #medicaldevice

i spent six months building something that should have taken six days.
not because the technology didn't work. because the last 10% of every AI project eats the first 90% alive.

a friend of mine calls it the 90/10 problem. you make incredible progress in the first few hours. you feel unstoppable. then you hit the wall — edge cases, security questions, integration failures, the stuff that doesn't show up in demos.
here's what i learned building a system that processes 881 days of screen recordings, 977 voice conversations, and pushes it all to a knowledge graph every morning at 6 AM:

the part that works is never the part that took the longest.
the part that took the longest is always the part nobody sees.
if you're building with AI right now and you feel like you're stuck at 90% — you're exactly where you're supposed to be.
the last 10% is where the real system lives.

p.s. wrote a deep dive on what happened when six AI power users got in a room together and compared notes. link in the first comment.

Watch out world, I'm a Master Builder on @Replit! (Powered by Anthropic)  https://lnkd.in/gmCR4izF

My Music Infrastructure Nobody Sees
25 hours of recorded mentoring sessions sitting on a hard drive.

89,835 files across 106 GB of creative assets scattered across Google Drive.
40+ conversations with timestamps, action items, and decisions — none of it connected.

That was yesterday.

Today, it's a single searchable system.

Here's what most people get wrong about knowledge management: they think the problem is having the information. It's not. The problem is that your best insights are trapped in formats that don't talk to each other.

A 2-hour recorded session contains maybe 15 minutes of genuinely unique insight. The rest is context, small talk, setup. But those 15 minutes? That's the intellectual property. That's what you paid for.

So we built a pipeline:

→ 22 recorded sessions processed into structured documents with exact timestamps, technique catalogs, and cross-session progress tracking

→ 89,835 files indexed from cloud storage into a searchable database with file types, folder paths, and metadata

→ Daily automation that syncs conversations, action items, and file changes every morning at 6 AM

→ A persistent memory layer that connects what was said with what was on screen at the time

The last point is the one nobody talks about. Context collapses when you separate audio from visuals. 

You can transcribe a conversation perfectly and still lose half the meaning because you don't know what the person was looking at when they said "do it like this."

We solved that by cross-referencing conversation timestamps against screen activity data. 

Now every action item carries the context of what was happening when it was created.

This isn't about being productive. This is about never losing signal again.
If you're sitting on hours of recorded calls, mentoring sessions, or workshops — the knowledge is already there. 

You just need an extraction layer that doesn't flatten it into a generic summary.

Build the system. 

The compound interest on organized knowledge is unreal.

What's the most valuable recording sitting on YOUR hard drive right now? 👇

#KnowledgeManagement #SystemsThinking #Automation #Productivity #WorkflowDesign #FutureOfWork #Music

The best AI isn't the one generating reports at 3am.
It's the one you forget is even there.

I've seen a lot of conversation about "always-on AI research bots" lately.
Set it up. Let it run. Wake up to 47 insight reports. Feel productive.

I get the appeal. But here's what I've learned from actually living with AI — not just using it at work:

My toothbrush tracks brushing pressure patterns.

My home gym adjusts resistance mid-rep based on fatigue.

My car drives itself on the highway.

My robot (3+ years now) monitors my home.

My production software analyzes frequency collisions in real-time.

My analysis engine maps FDA warning letters to quality system clauses in minutes — work that used to take consultants 4-6 hours per letter.

None of these are "research bots." None of them generate reports I'll never read.

They're embedded. They serve a specific function. And the human judgment is still the moat.

The gap isn't between "AI on" and "AI off."

It's between AI as a spectacle and AI as infrastructure.

One generates 47 reports overnight.

The other just... works.

The question isn't "should AI run 24/7?"

The question is: does each AI touchpoint serve a specific function where your expertise is the bottleneck?

If yes — let it run.

If no — you're just generating noise.

What's one AI tool you use that you genuinely forget is AI? 
I'll start — my toothbrush. Seriously.

keen to see how NVIDIA and Jensen Huang 's NemoClaw compares..

Transforming Data into Strategic Growth | Commercial Excellence Data & AI Leader I Advanced GenAI Expert

Is Claude becoming the operating system for Real-World Evidence? 🚀 

A recent update from Anthropic caught my attention — and it’s highly relevant for anyone working with real-world data (RWD), HEOR, and clinical development.

With the launch of Claude for Healthcare, we’re seeing a clear shift:
👉 from general-purpose LLMs → to domain-integrated intelligence platforms

What stands out?
🔹 Direct integration with healthcare data ecosystems
Clinical registries, coding systems (ICD-10), and payer data — moving closer to real-world data ingestion at scale.
🔹 Support for clinical trial design & augmentation
From protocol drafting to feasibility analysis using historical data — a strong signal toward RWE-powered trials.
🔹 Massive context windows (~1M tokens)
This changes the game for analyzing: (1) Longitudinal patient journeys, (2) Claims datasets, and (3) Full study reports in one pass.
🔹 Bridging clinical + consumer data
Early steps toward integrating wearable and patient-generated data — ключевой элемент для decentralized trials and digital biomarkers.

💡 Why this matters
We may be witnessing the emergence of a new layer in the RWE tech stack:
➡️ Not just storing data (Snowflake / Databricks)
➡️ Not just analyzing data (BI / stats tools)
➡️ But understanding and reasoning across it

🔖 Explore all strategic RWD use cases in the downloadable PDF report - https://lnkd.in/eBvMpntA
🔖 Explore RWD Data Solution Architecture with AI in the downloadable PDF report - https://lnkd.in/dTVxgUMi

📖 Full article here:
https://lnkd.in/dn_mwsqx
Curious to hear your perspective:

👉 Do you see GenAI becoming a core component of RWE platforms, or just an augmentation layer?
#RWE #RealWorldEvidence #RWD #HealthcareAI #ClinicalTrials #HEOR #GenAI #DigitalHealth

The shortest audit question with the longest silence:

"Show me how you decided what NOT to test."

That's it. One sentence.

Under CSV, nobody had to answer that. You tested everything on the script. Check the box. Move on.

Under CSA, that question is the whole point.

Critical thinking isn't about testing more. It's about documenting WHY you tested what you tested — and why you intentionally skipped what you skipped.

The companies getting this right aren't spending more time testing.
They're spending more time thinking before they test.

And that shift is exactly what most quality teams aren't prepared for.
If you're still testing from scripts and calling it "risk-based," I'd push back on that.

What's the hardest part of CSA adoption for your team? Genuinely curious.

A post by John Pryor caught my attention today.

He wrote about trade secrets hiding in plain sight
inside UK SMEs — how the real IP isn't patents
or trademarks. It's in pricing models,
customer strategies, and processes
nobody documented or protected.

He's right.

But I want to apply his argument
to an industry where the stakes are higher
and the blind spot is worse.

Medical devices.

I studied this in grad school.

My engineering law coursework at Northcentral University
(TIM-6220) opened with all four types
of intellectual property:
Patents. Trademarks. Copyrights. Trade secrets.

The course textbook — Ma's "Fundamentals of Patenting
and Licensing for Scientists and Engineers" —
frames IP through the lens of the patent value chain:
how inventors create IP that can be capitalized.

But what stuck with me most wasn't patents.

It was the trade secret material.

One of our required readings was McJohn's
"Top Tens in Patent, Trademark, Copyright,
and Trade Secret Cases" from the
Northwestern Journal of Technology
and Intellectual Property.

Real case law. Real disputes.
Real companies losing real value
over IP they didn't know they had
or didn't bother to protect.

My first assignment was conducting
an IP inventory for the Fortune 500
med-device company I was working at.

Not hypothetical. Real employer. Real IP.

I had to map patents, trade secrets,
copyrights, and trademarks
across the organization — and cite
why each example fell under its category.

That included analyzing trade secret litigation
where manufacturing process settings —
not products, not formulas —
process settings —
were disputed as protectable IP.

That changed how I think about
what a trade secret actually is.

Most people hear "trade secret"
and think Coca-Cola's formula.
Google's search algorithm.
KFC's 11 herbs and spices.

My Week 1 coursework covered the real definition.

Under the Uniform Trade Secrets Act (UTSA),
a trade secret has two requirements:

1. It derives economic value
  from not being generally known.

2. The holder takes reasonable measures
  to keep it secret.

No registration. No filing. No expiration.

The European IP Helpdesk — another course resource —
lays out the advantages and disadvantages plainly:

Trade secrets cost nothing to register.
They have no time limit.
But they're harder to enforce.
They can be independently discovered.
And if you fail to control access,
you lose protection entirely.

Now apply this to medical devices.

Think about what's inside your quality system:

→ SOPs that describe HOW your company makes
 a safe, effective medical device

→ Validation protocols documenting evidence
 that processes do what they claim

→ CAPA procedures defining how your organization
 identifies, investigates, and prevents failures

→ Work instructions, technical drawings,
 engineering change control processes
(CONTINUED IN COMMENTS..)

taplio

Neelank Tiwari, MS, PMP's Linkedin Analytics

Neelank Tiwari, MS, PMP

Performance ScoreNeelank Tiwari, MS, PMP's LinkedIn Performance

What is Neelank Tiwari, talking about?

Who is engaging with Neelank Tiwari,

Neelank Tiwari, MS, PMP's Best Posts (last 30 days)

Ready to grow your LinkedIn presence?